$ABCL
AbCellera Biologics Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022007077 Filed on February 25, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $139.3M $375.2M $200.9M
YoY Change -30.65% 60.92% 6178.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.72M $48.76M $8.000M
YoY Change 83.96% 208.61% 471.43%
% of Gross Profit
Research & Development $17.21M $62.06M $8.600M
YoY Change 100.1% 111.15% 160.61%
% of Gross Profit
Depreciation & Amortization $3.973M $4.400M $2.500M
YoY Change 58.92% 91.3% 525.0%
% of Gross Profit
Operating Expenses $57.78M $62.06M $47.10M
YoY Change 22.67% 111.15% 805.77%
Operating Profit $204.4M
YoY Change 31.01%
Interest Expense -$2.750M -$2.750M -$3.000M
YoY Change -8.33% -1.79% 1400.0%
% of Operating Profit -1.35%
Other Income/Expense, Net $5.907M $17.49M -$1.900M
YoY Change -410.89% 110.67% -480.0%
Pretax Income $84.71M $219.1M $155.9M
YoY Change -45.66% 38.85% -9843.75%
Income Tax $24.76M $65.69M $38.90M
% Of Pretax Income 29.23% 29.97% 24.95%
Net Earnings $59.95M $153.5M $117.0M
YoY Change -48.76% 29.05% -7412.5%
Net Earnings / Revenue 43.03% 40.9% 58.24%
Basic Earnings Per Share $0.56
Diluted Earnings Per Share $197.7K $0.48 $116.3K
COMMON SHARES
Basic Shares Outstanding 275.8M
Diluted Shares Outstanding 318.3M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $722.9M $476.1M $594.1M
YoY Change 21.69% -19.85%
Cash & Equivalents $476.1M $476.1M $900.0K
Short-Term Investments $246.8M $246.8M $900.0K
Other Short-Term Assets $21.25M $30.29M $5.970M
YoY Change 255.9% 404.88%
Inventory $1.672M $1.672M $1.400M
Prepaid Expenses $4.073M
Receivables $407.4M $407.4M $903.0K
Other Receivables $14.28M $14.28M $500.0K
Total Short-Term Assets $929.8M $929.8M $813.3M
YoY Change 14.32% 14.32%
LONG-TERM ASSETS
Property, Plant & Equipment $111.6M $111.6M $17.92M
YoY Change 522.75% 523.55%
Goodwill $47.81M $31.50M
YoY Change 51.77%
Intangibles $148.4M $115.2M
YoY Change 28.87%
Long-Term Investments $50.31M $50.31M $19.20M
YoY Change 162.05% 162.05%
Other Assets $30.64M $30.64M $8.388M
YoY Change 265.31% 264.79%
Total Long-Term Assets $388.8M $388.8M $192.2M
YoY Change 102.26% 102.27%
TOTAL ASSETS
Total Short-Term Assets $929.8M $929.8M $813.3M
Total Long-Term Assets $388.8M $388.8M $192.2M
Total Assets $1.319B $1.319B $1.006B
YoY Change 31.13% 31.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.92M $14.92M $7.100M
YoY Change 110.2% 110.2%
Accrued Expenses $0.00 $3.652M $700.0K
YoY Change -100.0% 421.71%
Deferred Revenue $7.536M $6.589M
YoY Change 14.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $190.0K
YoY Change
Total Short-Term Liabilities $120.7M $120.7M $103.5M
YoY Change 16.61% 16.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.200M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $1.733M $134.8M $6.620M
YoY Change -73.82% 212.01%
Total Long-Term Liabilities $172.2M $134.8M $71.54M
YoY Change 140.66% 196.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $120.7M $120.7M $103.5M
Total Long-Term Liabilities $172.2M $134.8M $71.54M
Total Liabilities $292.8M $292.8M $175.0M
YoY Change 67.31% 67.33%
SHAREHOLDERS EQUITY
Retained Earnings $267.7M $114.2M
YoY Change 134.38%
Common Stock $757.8M $716.3M
YoY Change 5.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.026B $1.026B $830.5M
YoY Change
Total Liabilities & Shareholders Equity $1.319B $1.319B $1.006B
YoY Change 31.13% 31.14%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income $59.95M $153.5M $117.0M
YoY Change -48.76% 29.05% -7412.5%
Depreciation, Depletion And Amortization $3.973M $4.400M $2.500M
YoY Change 58.92% 91.3% 525.0%
Cash From Operating Activities -$16.71M $244.6M $1.300M
YoY Change -1385.54% 977.94% 160.0%
INVESTING ACTIVITIES
Capital Expenditures -$9.430M -$58.45M -$1.500M
YoY Change 528.67% -704.28% 150.0%
Acquisitions $11.46M
YoY Change -86.93%
Other Investing Activities $8.281M -$273.8M -$106.7M
YoY Change -107.76% 160.48% 106600.0%
Cash From Investing Activities -$1.149M -$332.2M -$108.2M
YoY Change -98.94% 177.38% 17933.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $1.823M
YoY Change -90.86%
Cash From Financing Activities 1.834M -3.886M 610.0M
YoY Change -99.7% -100.57% 203233.33%
NET CHANGE
Cash From Operating Activities -16.71M 244.6M 1.300M
Cash From Investing Activities -1.149M -332.2M -108.2M
Cash From Financing Activities 1.834M -3.886M 610.0M
Net Change In Cash -16.03M -92.97M 503.1M
YoY Change -103.19% -115.85% 251450.0%
FREE CASH FLOW
Cash From Operating Activities -$16.71M $244.6M $1.300M
Capital Expenditures -$9.430M -$58.45M -$1.500M
Free Cash Flow -$7.282M $303.0M $2.800M
YoY Change -360.07% 2228.0% 154.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 abcl Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
594116000
CY2020Q4 abcl Accounts And Accrued Receivable Current
AccountsAndAccruedReceivableCurrent
213239000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
25000000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5970000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
21247000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
813325000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
929800000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17923000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111616000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
115153000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
148392000
CY2020Q4 us-gaap Goodwill
Goodwill
31500000
CY2021Q4 us-gaap Goodwill
Goodwill
47806000
CY2020Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
19247000
CY2021Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
50313000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8388000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30642000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
192211000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
388769000
CY2020Q4 us-gaap Assets
Assets
1005536000
CY2021Q4 us-gaap Assets
Assets
1318569000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1733000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
20195000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
32017000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
13411000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
22934000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
36152000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
35683000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
27143000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6589000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
103490000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3715000
CY2020Q4 abcl Deferred Revenue And Grant Funding Noncurrent
DeferredRevenueAndGrantFundingNoncurrent
25894000
CY2021Q4 abcl Deferred Revenue And Grant Funding Noncurrent
DeferredRevenueAndGrantFundingNoncurrent
60758000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
9148000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
35886000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
26161000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
37370000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6620000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
71538000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
172160000
CY2020Q4 us-gaap Liabilities
Liabilities
175028000
CY2021Q4 us-gaap Liabilities
Liabilities
292836000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
269497768
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
269497768
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
283257104
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
283257104
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
710387000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
722430000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5919000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35357000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
280000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
114202000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
267666000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
830508000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1025733000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1005536000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1318569000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11612000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
233155000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
375203000
CY2020 us-gaap Royalty Expense
RoyaltyExpense
27143000
CY2021 us-gaap Royalty Expense
RoyaltyExpense
45516000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29393000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62062000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6913000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-4117000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
155000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
293000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
3330000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
186000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-300000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-855000
CY2021 abcl Grants And Incentives
GrantsAndIncentives
17486000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151327560
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
280000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2211000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
118918000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11609000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.53
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10252000
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159195023
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
275763745
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151327560
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
840000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
263129765
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
318294236
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2019 abcl Stock Issuance Costs
StockIssuanceCosts
11000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-2211000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74662000
CY2020 us-gaap Depreciation
Depreciation
2317000
CY2020 us-gaap Profit Loss
ProfitLoss
118918000
CY2021 us-gaap Profit Loss
ProfitLoss
153464000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
118918000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
830508000
CY2021 abcl Stock Issued During Period Value Stock Options And Other
StockIssuedDuringPeriodValueStockOptionsAndOther
6566000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29240000
CY2021 abcl Adjustments To Additional Paid In Capital Reclassification Of Liability Classified Options
AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions
5675000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
280000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1025733000
CY2019 us-gaap Profit Loss
ProfitLoss
-2211000
CY2019 us-gaap Depreciation
Depreciation
1604000
CY2021 us-gaap Depreciation
Depreciation
4403000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2519000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10062000
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
243000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
435000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2785000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
890000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
8397000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
30646000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2098000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2018000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-194000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4707000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3570000
CY2019 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1803000
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
5467000
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
37386000
CY2020 abcl Increase Decrease In Accrued Royalties Receivable
IncreaseDecreaseInAccruedRoyaltiesReceivable
197553000
CY2021 abcl Increase Decrease In Accrued Royalties Receivable
IncreaseDecreaseInAccruedRoyaltiesReceivable
-59864000
CY2020 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
36412000
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-13530000
CY2019 abcl Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
150000
CY2020 abcl Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
6601000
CY2021 abcl Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
1400000
CY2019 abcl Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2784000
CY2020 abcl Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-350000
CY2021 abcl Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-778000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
21810000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8624000
CY2020 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
27143000
CY2021 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
-4637000
CY2020 abcl Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
6763000
CY2021 abcl Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
-30718000
CY2019 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-849000
CY2020 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1466000
CY2021 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
2603000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2694000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22690000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
244584000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3997000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9673000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5000000
CY2019 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
-1783000
CY2020 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
1783000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
274710000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27608000
CY2021 abcl Proceeds From Receipt Of Grant Funding
ProceedsFromReceiptOfGrantFunding
32621000
CY2020 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
87643000
CY2021 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
11457000
CY2021 abcl Payments To Acquire Long Term Investments And Other Assets
PaymentsToAcquireLongTermInvestmentsAndOtherAssets
17534000
CY2020 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
19247000
CY2021 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
30323000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5780000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119780000
CY2021 abcl Payment Of Liability For In Licensing Agreement
PaymentOfLiabilityForInLicensingAgreement
5000000
CY2019 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
387000
CY2020 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-387000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4615000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
522840000
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
-11000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
74662000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
195000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-332247000
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
399000
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
19942000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1823000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
193000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
15490000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
872000
CY2020 abcl Proceeds From Convertible Debentures
ProceedsFromConvertibleDebentures
89990000
CY2021 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2550000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
683653000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3886000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1425000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2891000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
586563000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-92974000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10444000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7553000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
594116000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7553000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
594116000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
501142000
CY2019 abcl Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable
NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
35000
CY2020 abcl Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable
NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
656000
CY2021 abcl Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable
NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
5397000
CY2019 abcl Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation
NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
2830000
CY2020 abcl Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation
NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
1679000
CY2021 abcl Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation
NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
36638000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
9060000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">1. Nature of operations</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">AbCellera Biologics Inc.’s (the “Company”) mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. The Company aims to become the centralized operating system for next generation antibody discovery. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The Company believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing its own clinical pipeline of drug candidates, the Company forges partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies.  </span></p>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
375600000
CY2020Q4 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
1-for-10
CY2020Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2021Q4 abcl Company Contributed Segregated Account Representing Loss
CompanyContributedSegregatedAccountRepresentingLoss
25000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:1.69%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determining whether an option for additional </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services represents a material right, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fair</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> value of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquired intangible assets, and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contingent consideration payable</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimates</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facts</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates. </span></p>
CY2020Q4 us-gaap Cash
Cash
593700000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
400000
CY2021Q4 us-gaap Cash
Cash
100500000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
25000000.0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2020 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
63260090
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.50
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151327560
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-2211000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
118918000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
153464000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
33817000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2211000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
85101000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
153464000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151327560
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159195023
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
275763745
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.53
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2211000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
118918000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
153464000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
151327560
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159195023
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
275763745
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
40674652
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
42530491
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
263129765
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
318294236
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58411640
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
908409
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
489000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
14282000
CY2020Q4 abcl Prepaid Expense And Other Current
PrepaidExpenseAndOtherCurrent
4073000
CY2021Q4 abcl Prepaid Expense And Other Current
PrepaidExpenseAndOtherCurrent
5293000
CY2020Q4 abcl Materials And Supplies Current
MaterialsAndSuppliesCurrent
1408000
CY2021Q4 abcl Materials And Supplies Current
MaterialsAndSuppliesCurrent
1672000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5970000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
21247000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
780000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
6764000
CY2020Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
675000
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2875000
CY2020Q4 us-gaap Security Deposit
SecurityDeposit
1035000
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
13595000
CY2020Q4 abcl Deferred Tax Assets Other Long Term Assets
DeferredTaxAssetsOtherLongTermAssets
5898000
CY2021Q4 abcl Deferred Tax Assets Other Long Term Assets
DeferredTaxAssetsOtherLongTermAssets
7408000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8388000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30642000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23509000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
121442000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5586000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9826000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17923000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111616000
CY2021Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
19800000
CY2019 us-gaap Depreciation
Depreciation
1600000
CY2020 us-gaap Depreciation
Depreciation
2300000
CY2021 us-gaap Depreciation
Depreciation
4400000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
117673000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2520000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
115153000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
160973000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12581000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
148392000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2500000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10100000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
10425000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
10425000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5610000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4041000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4041000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
34542000
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
31500000
CY2020Q4 us-gaap Goodwill
Goodwill
31500000
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
16306000
CY2021Q4 us-gaap Goodwill
Goodwill
47806000
CY2021 abcl Number Of Joint Ventures
NumberOfJointVentures
2
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7320000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14924000
CY2020Q4 abcl Liability For In Licensing Agreement Current
LiabilityForInLicensingAgreementCurrent
5000000
CY2021Q4 abcl Liability For In Licensing Agreement Current
LiabilityForInLicensingAgreementCurrent
4933000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
675000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3652000
CY2020Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
4270000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1988000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4035000
CY2020Q4 abcl Deferred Grant Funding Current
DeferredGrantFundingCurrent
942000
CY2021Q4 abcl Deferred Grant Funding Current
DeferredGrantFundingCurrent
4473000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
20195000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
32017000
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
269497768
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
269497768
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
283257104
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
283257104
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each voting common share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders.
CY2021 us-gaap Dividends Cash
DividendsCash
0
CY2021Q1 abcl Conversion Of Liability Classified Options To Equity
ConversionOfLiabilityClassifiedOptionsToEquity
5700000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
890000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8397000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30646000
CY2021 us-gaap Dividends
Dividends
0
CY2020Q4 abcl Deferred Compensation Share Based Arrangements Liability Classified Noncurrent Outstanding
DeferredCompensationShareBasedArrangementsLiabilityClassifiedNoncurrentOutstanding
1012000
CY2020Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
4300000
CY2021Q4 abcl Deferred Compensation Share Based Arrangements Liability Classified Noncurrent Outstanding
DeferredCompensationShareBasedArrangementsLiabilityClassifiedNoncurrentOutstanding
0
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
26321000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
34954000
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2100000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000.0
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4700000
CY2020 abcl Received Funding Commitment
ReceivedFundingCommitment
175600000
CY2020 abcl Received Funding Commitment
ReceivedFundingCommitment
125600000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0
CY2021 abcl Strategic Innovation Fund Eligible Expenditure
StrategicInnovationFundEligibleExpenditure
47100000
CY2021 abcl Research And Development Eligible Expenditure
ResearchAndDevelopmentEligibleExpenditure
13800000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33300000
CY2021 abcl Capital Asset Expenditures Amortize Over Average Asset Life Period
CapitalAssetExpendituresAmortizeOverAverageAssetLifePeriod
P5Y
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2015000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
163077000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
211471000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-196000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5244000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
7678000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2211000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
157833000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
219149000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
36931000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
60498000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-114000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
7248000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
36817000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
67746000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2461000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1342000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-363000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-719000
CY2020 abcl Deferred And Other Income Tax Expense Benefit
DeferredAndOtherIncomeTaxExpenseBenefit
2098000
CY2021 abcl Deferred And Other Income Tax Expense Benefit
DeferredAndOtherIncomeTaxExpenseBenefit
-2061000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38915000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65685000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
36817000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
67746000
CY2020 abcl Deferred And Other Income Tax Expense Benefit
DeferredAndOtherIncomeTaxExpenseBenefit
2098000
CY2021 abcl Deferred And Other Income Tax Expense Benefit
DeferredAndOtherIncomeTaxExpenseBenefit
-2061000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38915000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65685000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-680000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5007000
CY2019 abcl Effective Income Tax Rate Reconciliation At Change For Under Accrual
EffectiveIncomeTaxRateReconciliationAtChangeForUnderAccrual
49000
CY2020 abcl Effective Income Tax Rate Reconciliation At Change For Under Accrual
EffectiveIncomeTaxRateReconciliationAtChangeForUnderAccrual
36000
CY2021 abcl Effective Income Tax Rate Reconciliation At Change For Under Accrual
EffectiveIncomeTaxRateReconciliationAtChangeForUnderAccrual
1000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
510000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1698000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4809000
CY2019 abcl Effective Income Tax Rate Reconciliation At Foreign Exchange
EffectiveIncomeTaxRateReconciliationAtForeignExchange
-9000
CY2020 abcl Effective Income Tax Rate Reconciliation At Foreign Exchange
EffectiveIncomeTaxRateReconciliationAtForeignExchange
-4048000
CY2021 abcl Effective Income Tax Rate Reconciliation At Foreign Exchange
EffectiveIncomeTaxRateReconciliationAtForeignExchange
47000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-41000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
756000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-738000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38915000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65685000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2211000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
157833000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
219149000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-597000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
42615000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
59170000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
254000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
1934000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
7007000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
854000
CY2020Q4 abcl Deferred Tax Assets Long Term Debt
DeferredTaxAssetsLongTermDebt
2590000
CY2021Q4 abcl Deferred Tax Assets Long Term Debt
DeferredTaxAssetsLongTermDebt
6293000
CY2020Q4 abcl Deferred Tax Assets Financing Fee
DeferredTaxAssetsFinancingFee
6786000
CY2021Q4 abcl Deferred Tax Assets Financing Fee
DeferredTaxAssetsFinancingFee
6575000
CY2020Q4 abcl Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
1182000
CY2021Q4 abcl Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
5299000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4768000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
408000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4996000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
949000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3019000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11915000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30950000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
707000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3256000
CY2021Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
2135000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
26300000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
36866000
CY2020Q4 abcl Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
1084000
CY2021Q4 abcl Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
4732000
CY2020Q4 abcl Deferred Tax Liabilities Government Funding Receivable
DeferredTaxLiabilitiesGovernmentFundingReceivable
3279000
CY2021Q4 abcl Deferred Tax Liabilities Government Funding Receivable
DeferredTaxLiabilitiesGovernmentFundingReceivable
3029000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
41000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1661000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31411000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9200000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
51679000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
1500000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
19496000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
1500000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
18200000
CY2020Q4 abcl Deferred Tax Assets Other Long Term Assets
DeferredTaxAssetsOtherLongTermAssets
5900000
CY2021Q4 abcl Deferred Tax Assets Other Long Term Assets
DeferredTaxAssetsOtherLongTermAssets
7400000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
26200000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
37400000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
800000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
20729000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
767000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9233000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
20263000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
29962000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11148000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
21717000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31411000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
51679000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
20263000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
29962000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
448000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
387000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
109000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
387000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
109000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
448000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
387000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
109000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
387000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
109000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
675000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3652000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3715000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36413000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4390000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
40065000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4623000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4796000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5070000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4980000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4694000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
22133000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.033
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
4100000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
22600000
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Royalty Expense
RoyaltyExpense
27100000
CY2021 us-gaap Royalty Expense
RoyaltyExpense
45500000
CY2019 us-gaap Royalty Expense
RoyaltyExpense
0
CY2020Q4 abcl Accounts And Accrued Royalty Receivable Amounts Due Number Of Customers
AccountsAndAccruedRoyaltyReceivableAmountsDueNumberOfCustomers
7
CY2021Q4 abcl Accounts And Accrued Royalty Receivable Amounts Due Number Of Customers
AccountsAndAccruedRoyaltyReceivableAmountsDueNumberOfCustomers
13
CY2021 abcl Recognized Milestone Payments
RecognizedMilestonePayments
7000000.0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
476100000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
25000000.0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
246800000
CY2021Q4 us-gaap Investment Interest Rate
InvestmentInterestRate
0.10
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
900000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8200000

Files In Submission

Name View Source Status
0001564590-22-007077-index-headers.html Edgar Link pending
0001564590-22-007077-index.html Edgar Link pending
0001564590-22-007077.txt Edgar Link pending
0001564590-22-007077-xbrl.zip Edgar Link pending
abcl-10k_20211231.htm Edgar Link pending
abcl-10k_20211231_htm.xml Edgar Link completed
abcl-20211231.xsd Edgar Link pending
abcl-20211231_cal.xml Edgar Link unprocessable
abcl-20211231_def.xml Edgar Link unprocessable
abcl-20211231_lab.xml Edgar Link unprocessable
abcl-20211231_pre.xml Edgar Link unprocessable
abcl-ex231_174.htm Edgar Link pending
abcl-ex311_173.htm Edgar Link pending
abcl-ex312_172.htm Edgar Link pending
abcl-ex321_171.htm Edgar Link pending
abcl-ex322_170.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gbhwlkegehwl000001.jpg Edgar Link pending
gbhwlkegehwl000002.jpg Edgar Link pending
gbhwlkegehwl000003.jpg Edgar Link pending
gbhwlkegehwl000004.jpg Edgar Link pending
gbhwlkegehwl000005.jpg Edgar Link pending
gbhwlkegehwl000006.jpg Edgar Link pending
gbhwlkegehwl000007.jpg Edgar Link pending
gbhwlkegehwl000008.jpg Edgar Link pending
gbhwlkegehwl000009.jpg Edgar Link pending
gbhwlkegehwl000010.jpg Edgar Link pending
gbhwlkegehwl000011.jpg Edgar Link pending
gbhwlkegehwl000012.jpg Edgar Link pending
gbhwlkegehwl000013.jpg Edgar Link pending
gbhwlkegehwl000014.jpg Edgar Link pending
gbhwlkegehwl000015.jpg Edgar Link pending
gbhwlkegehwl000016.jpg Edgar Link pending
gbhwlkegehwl000017.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending